Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 2,747,600 shares, a decrease of 9.1% from the August 15th total of 3,022,000 shares. Based on an average daily trading volume, of 2,200 shares, the days-to-cover ratio is currently 1,248.9 days.

Innovent Biologics Stock Performance

Shares of IVBXF opened at $5.58 on Wednesday. Innovent Biologics has a 12 month low of $3.83 and a 12 month high of $6.41. The business’s fifty day simple moving average is $5.26 and its two-hundred day simple moving average is $5.00.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.